Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    7 0 0 0

Archives de pédiatrie
Volume 20, n° 4
pages 405-411 (avril 2013)
Doi : 10.1016/j.arcped.2013.01.021
Received : 27 January 2012 ;  accepted : 21 January 2013
L’allogreffe de cellules souches hématopoïétiques en 2012 : pour qui ? Comment ? Dans quelles conditions ?
Hematopoietic stem cell transplantation in 2012: Who? Where? How?

J.-H. Dalle
Service d’hématologie et immunologie pédiatrique, université Paris Denis-Diderot, hôpital Robert-Debré, 48, boulevard Serurier, 75935 Paris cedex 19, France 


L’allogreffe de cellules souches hématopoïétiques a beaucoup évolué depuis ses origines, multipliant les sources cellulaires utilisables (moelle, cellules souches périphériques, sang placentaire), les donneurs mobilisables (intrafamiliaux, non apparentés, totalement ou partiellement compatibles) et les modalités thérapeutiques entourant la greffe (immunosuppresseurs, manipulations du greffon, soins de support), ouvrant la voie à un ensemble vaste de thérapies cellulaires. Les pathologies pour lesquelles une greffe est indiquée sont de plus en plus nombreuses : hémopathies malignes, hémopathies bénignes sévères telles que les aplasies médullaires congénitales ou acquises, les hémoglobinopathies ou encore les déficits immunitaires sévères et certaines maladies de surcharge. Cet article se propose d’offrir un tour d’horizon complet de cette technique pour l’enfant en 2012.

The full text of this article is available in PDF format.

Allogeneic bone marrow transplantation has dramatically changed over the years since its beginnings. The diseases treated with transplantation (malignant hemopathies, severe benign hemopathies such as congenital or acquired congenital medullary aplasia, hemoglobinopathies, as well as severe immune system deficiencies and certain overload diseases), stem cell sources (bone marrow, peripheral stem cells, placental blood), donor types (intrafamilial, nonrelated, totally or partially compatible), conditioning regimen (immunosuppressors, graft manipulation), and supportive care increasingly vary. Allogeneic stem cell transplantation and more widely cellular therapies now need to be discussed. In this paper, we propose an overview of these therapies in 2012 for pediatric patients.

The full text of this article is available in PDF format.

© 2013  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline